Drug Type Small molecule drug |
Synonyms LY 2090314, LY2090314 |
Target |
Action inhibitors |
Mechanism GSK-3 inhibitors(Glycogen synthase kinase-3 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H25FN6O3 |
InChIKeyHRJWTAWVFDCTGO-UHFFFAOYSA-N |
CAS Registry603288-22-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Pancreatic Cancer | Phase 2 | United States | 01 Mar 2013 | |
acute leukemia | Phase 2 | United States | 01 Nov 2010 | |
Advanced cancer | Phase 1 | United States | 01 Nov 2007 |
Phase 2 | 20 | (Cohort 1, 40 mg LY2090314: D1, D8, D15) | umamgnygzc = sflphasodu plasybzmpa (mxfkjlcoas, mzlrwebtuv - dehtmtmeep) View more | - | 19 Nov 2018 | ||
(Cohort 2, 40 mg LY2090314: D1, D5, D9) | umamgnygzc = mamvphtevx plasybzmpa (mxfkjlcoas, zbuoznrnmv - sphommpyfj) View more | ||||||
Phase 1/2 | 13 | (LY2090314 + Gemcitabine) | ixbwznptal(demoxebrkf) = nqztondsla pxtnsmuxbv (mvkozplpep, apupvvytkt - kuhivbbeaj) View more | - | 19 Nov 2018 | ||
(LY2090314 + FOLFOX) | ixbwznptal(demoxebrkf) = kkphzmdclw pxtnsmuxbv (mvkozplpep, pwhldnkkyu - hsfzbknrco) View more | ||||||
Phase 1 | 78 | qhyvhlpfxr(mnkuucvbae) = mqsnxeerhh uvggrjlzit (jtvbitkfdu ) View more | Positive | 01 Dec 2015 |